Biomaterials and Nanomedicine , Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Barcelona Science Park , 08028 Barcelona , Spain.
Combinatorial Chemistry Unit , Barcelona Science Park , 08028 Barcelona , Spain.
J Med Chem. 2018 Oct 25;61(20):9335-9346. doi: 10.1021/acs.jmedchem.8b01249. Epub 2018 Oct 11.
Bivalent ligands have emerged as chemical tools to study G protein-coupled receptor dimers. Using a combination of computational, chemical, and biochemical tools, here we describe the design of bivalent ligand 13 with high affinity ( K = 21 pM) for the dopamine D receptor (DR) homodimer. Bivalent ligand 13 enhances the binding affinity relative to monovalent compound 15 by 37-fold, indicating simultaneous binding at both protomers. Using synthetic peptides with amino acid sequences of transmembrane (TM) domains of DR, we provide evidence that TM6 forms the interface of the homodimer. Notably, the disturber peptide TAT-TM6 decreased the binding of bivalent ligand 13 by 52-fold and had no effect on monovalent compound 15, confirming the DR homodimer through TM6 ex vivo. In conclusion, by using a versatile multivalent chemical platform, we have developed a precise strategy to generate a true bivalent ligand that simultaneously targets both orthosteric sites of the DR homodimer.
双价配体已成为研究 G 蛋白偶联受体二聚体的化学工具。在这里,我们结合使用计算、化学和生化工具,描述了具有高亲和力(K = 21 pM)的二价配体 13 的设计,该配体可用于多巴胺 D 受体(DR)同源二聚体。二价配体 13 使结合亲和力相对于单价化合物 15 增强了 37 倍,表明同时结合在两个前体上。使用具有 DR 跨膜(TM)结构域氨基酸序列的合成肽,我们提供了证据表明 TM6 形成了同源二聚体的界面。值得注意的是,干扰肽 TAT-TM6 使二价配体 13 的结合降低了 52 倍,而对单价化合物 15 没有影响,这在体外证实了 DR 同源二聚体的存在。总之,通过使用多功能多价化学平台,我们开发了一种精确的策略,可生成同时靶向 DR 同源二聚体两个正位点的真正双价配体。